Key facts
- This page summarizes Gary M. Rauch's Form 4 filing for TNF Pharmaceuticals, Inc. (TNFA).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 18 Apr 2025, 16:30.
Gary M. Rauch - 17 Apr 2025 Form 4 Insider Report for TNF Pharmaceuticals, Inc. (TNFA)
- Reporting relationship
- Vice President, Finance
- Issuer ticker
- TNFA
- Reported as of
- 17 Apr 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 18 Apr 2025, 16:30:15 UTC
- Next SEC filing
- 06 Oct 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Gary Rauch
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Gary M. Rauch filed Form 4 for TNF Pharmaceuticals, Inc. (TNFA) on 18 Apr 2025.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TNFA
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +75,000
- Change %
- Price
- $0.000000
- Shares after
- 75,000
- Date
- 17 Apr 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 75,000
- Exercise price
- $0.1832
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The stock options are subject to expiration if the employment of the Reporting Person is terminated.